Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for gp130/IL6ST drug discovery. Select your therapeutic modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | gp130/IL6ST ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View IL6ST Products |
| Gene Delivery | gp130/IL6ST Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and signaling assays. |
View IL6ST Products |
| Benchmark Ab | Anti-gp130 Recombinant Antibody (Olamkicept biosimilar sequence) Recombinant positive control for blocking and binding validation. |
View IL6ST Products |
| Validator | gp130/IL6ST siRNA Set For target knockdown and specificity verification in cell-based assays. |
View IL6ST Products |
| Related Target A | IL6R Essential co-receptor forming the classic and trans-signaling complex with gp130. |
View IL6R Products |
| Related Target B | IL6 Primary upstream cytokine driver of the IL-6R/gp130 signaling cascade. |
View IL6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity between classic and trans-signaling | High-purity soluble gp130-Fc proteins available to mimic endogenous trans-signaling decoy activity. |
| Subfamily cross-reactivity screening | Homolog panel proteins (LIFR, OSMR) strictly verified by mass spectrometry to exclude off-target binding. |
| Lack of standardized positive controls | Clinical Benchmark Antibodies (Biosimilars) sequence-verified and recombinantly expressed. |
| False positives in phenotypic screens | Sequence-validated siRNA pools included for target-specific knockdown validation. |
Live gp130/IL6ST R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for gp130/IL6ST therapeutics is intensifying, with major players shifting focus from systemic IL-6/IL-6R blockade to selective gp130 trans-signaling inhibition. As first-generation global biologics target broad inflammatory pathways, the next wave of R&D is targeting tissue-specific gp130 complexes to avoid systemic immunosuppression and hematological toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Soluble gp130-Fc Fusion | Ferring Pharmaceuticals, I-Mab Biopharma | Inflammatory Bowel Disease (IBD), Ulcerative Colitis | Trans-signaling selective inhibition assays (Need high-purity monomeric and dimeric gp130-Fc) |
| Monoclonal Antibodies | Invenra, various academic consortia | Autoimmune diseases, Solid Tumors | Epitope mapping and receptor dimerization blockade (Need Lentivirus for stable cell lines) |
| Bispecific Biologics | Biotech startups | Oncology, Fibrosis | Heterodimer validation and dual-targeting kinetics (Need cross-reactive IL-6R and gp130 proteins) |